anastrozole / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 0 Diseases   123 Trials   123 Trials   2738 News 


«12...678910111213141516...4142»
  • ||||||||||  Mekinist (trametinib) / Novartis, Keytruda (pembrolizumab) / Merck (MSD)
    Clinical, Journal, PD(L)-1 Biomarker:  Update on new treatments for rare ovarian tumours. (Pubmed Central) -  Nov 29, 2022   
    The last few years have exhibited a paradigm shift towards the possibility to develop dedicated trials for ROT, owing to international collaborations supported by institutional networks. Current trials, molecular-driven and based on innovative designs, are highly promising, as they may bring ROT management towards more personalized medicine.
  • ||||||||||  anastrozole / Generic mfg., gemcitabine / Generic mfg.
    Journal:  A naïve pooled data approach for extrapolation of Phase 0 microdose trials to therapeutic dosing regimens. (Pubmed Central) -  Nov 25, 2022   
    This study demonstrated the possible use and feasibility of an NPD modeling approach for the evaluation and application of microdose studies in early drug development. Last, physiologically-based pharmacokinetic modeling might be an alternative for microdose extrapolation of drugs with complex pharmacokinetics such as gemcitabine.
  • ||||||||||  camizestrant (AZD9833) / AstraZeneca
    Enrollment change, Trial completion date, Trial primary completion date:  SERENA-1: Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer. (clinicaltrials.gov) -  Nov 25, 2022   
    P1,  N=402, Recruiting, 
    Last, physiologically-based pharmacokinetic modeling might be an alternative for microdose extrapolation of drugs with complex pharmacokinetics such as gemcitabine. N=305 --> 402 | Trial completion date: Dec 2023 --> Apr 2024 | Trial primary completion date: Dec 2023 --> Mar 2024
  • ||||||||||  Lynparza (olaparib) / Merck (MSD), AstraZeneca
    Journal:  Breast and Advanced Ovarian Double Cancer with a BRCA2 Pathogenic Variant-A Case Report (Pubmed Central) -  Nov 23, 2022   
    Once adjuvant chemotherapy for ovarian cancer had been completed, a left mastectomy and sentinel lymph node biopsy were performed as management for breast cancer. The patient will continue treatment with anastrozole for breast cancer and olaparib for ovarian cancer and will be followed up appropriately.
  • ||||||||||  anastrozole / Generic mfg.
    Characteristics of patients with metastatic luminal breast cancer (MLBC) and ESR1 polymorphism (Exhibition Hall) -  Nov 23, 2022 - Abstract #EBCC2022EBCC_468;    
    First line HT was started with nonsteroidal AI (lertozole/anastrozole)... There was no statistically significant association of ESR1 (A-351G, T-397C) polymorphisms with the patients’ clinical characteristics (MP, BMI, smoking experience, family cancer history) apart from an accompanying gynecological pathology, which may point out the indirect relation of gynecological disorders in the anamnesis and acquired insensitivity to IA HT, in particular, due to ESR1 gene polymorphisms.
  • ||||||||||  Verzenio (abemaciclib) / Eli Lilly
    Abemaciclib for treating patients with HR+, HER2- advanced/metastatic breast cancer in Spain: a real-world study (Exhibition Hall) -  Nov 23, 2022 - Abstract #EBCC2022EBCC_366;    
    Abemaciclib, used in different lines of treatment and mostly in combination with AIs or fulvestrant, in a real-world setting in patients with HR+, HER2- ABC/MBC in Spain, was associated with a median PFS of 21.5 months and complete or partial response of 42.8%. These data are comparable to data from clinical trials supporting the benefit of abemaciclib for patients with HR+, HER2- ABC/MBC.
  • ||||||||||  anastrozole / Generic mfg.
    The Effect of Anastrozole Treatment on Height Gain in Pubertal Boys on Growth Hormone Treatment (Rome, Italy) -  Nov 13, 2022 - Abstract #ESPE2022ESPE_1581;    
    This study provides RiBi-based markers relevant for a better selection of patients with advanced endometrial carcinoma by predicting the response of endocrine therapy combined with mTOR inhibitor. It has been apparently shown that although the use of anastrozole for at least 2 years in addition to GH does not affect growth rate, it slows down the advancement in BA, thus, resulting in gain in FH.
  • ||||||||||  anastrozole / Generic mfg., triptorelin / Generic mfg., bicalutamide / Generic mfg.
    Pubertal dysfunctions in intracranial germ cell tumours (Rome, Italy) -  Nov 13, 2022 - Abstract #ESPE2022ESPE_1424;    
    Patients with IC-GCTs are at risk of pubertal dysfunctions, especially suprasellar germinomas. Associated pubertal disorders can be heterogeneous, from HCG-driven PPP to CPP or HH, and may change over time, therefore specialist follow-up is required.
  • ||||||||||  anastrozole / Generic mfg.
    A Rare and Treatable Cause of Prepubertal Gynecomastia: Large Cell Calcifying Sertoli Cell Tumor (Rome, Italy) -  Nov 13, 2022 - Abstract #ESPE2022ESPE_1131;    
    Testicular tumor should be investigated in a patient with PJS who presents with prepubertal gynecomastia. When findings are consistent with LCCSCT, biopsy may not be needed and aromatase inhibitors may be preferred in the treatment to reduce gynecomastia and delay skeletal maturation.
  • ||||||||||  anastrozole / Generic mfg.
    Case Series: Anastrozole Monotherapy for Non-Classic Congenital Adrenal Hyperplasia (Rome, Italy) -  Nov 13, 2022 - Abstract #ESPE2022ESPE_582;    
    Monotherapy with AI can be an effective alternative in slowing down bone maturation and improving height outcomes in children with NC-CAH and normal adrenal cortisol production. All three patients had appropriate pubertal progression, normal ovarian ultrasounds, and normal bone mineral density accrual.
  • ||||||||||  letrozole / Generic mfg., anastrozole / Generic mfg.
    Journal:  Effect of Aromatase Inhibitors on Serum Calprotectin Levels in an Animal Experimental Model: Trial. (Pubmed Central) -  Nov 8, 2022   
    Anastrazole, an aromatase inhibitor, is effective in slowing bone maturation during pathological adrenarche in patients with SRS or PWS. The potential of hepatotoxicity can be examined by assessing the elevation of inflammation markers such as Calprotectin, which is an indicator that should be strictly taken into consideration when administering aromatase inhibitors as treatment.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Verzenio (abemaciclib) / Eli Lilly
    P1 data, Journal, Combination therapy:  Abemaciclib in combination with pembrolizumab for HR+, HER2- metastatic breast cancer: Phase 1b study. (Pubmed Central) -  Nov 7, 2022   
    P1b
    Abemaciclib plus pembrolizumab demonstrated antitumor activity, but high rates of ILD/pneumonitis and severe transaminase elevations occurred with/without anastrozole compared to the previous reporting. Benefit/risk analysis does not support further evaluation of this combination in the treatment of HR+, HER2- MBC.
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion date, Trial primary completion date, Metastases:  POLLY: ER Reactivation Therapy for Breast Cancer (clinicaltrials.gov) -  Nov 3, 2022   
    P2,  N=19, Active, not recruiting, 
    Not yet recruiting --> Recruiting Trial completion date: Sep 2022 --> Sep 2023 | Trial primary completion date: Jun 2022 --> May 2023
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    A CASE OF PSEUDOCIRRHOSIS IN METASTATIC BREAST CANCER AFTER TREATMENT WITH PALBOCICLIB () -  Oct 23, 2022 - Abstract #AASLD2022AASLD_2198;    
    This case of pseudocirrhosis, with advanced GI and peritoneal metastases but no overt liver lesions, supports previous literature. The primary site of toxic injury is suspected to be sinusoidal endothelial cells with resultant circulatory compromise of centrilobular hepatocytes, fibrosis, and obstruction of liver blood flow.
  • ||||||||||  anastrozole / Generic mfg.
    Preclinical, Journal:  27-Hydroxycholesterol-Induced Dysregulation of Cholesterol Metabolism Impairs Learning and Memory Ability in ApoE ε4 Transgenic Mice. (Pubmed Central) -  Oct 22, 2022   
    Here, 12-month-old ApoE ε4 transgenic mice were injected with saline, 27-OHC, 27-OHC synthetase inhibitor (anastrozole, ANS), and 27-OHC+ANS for 21 consecutive days...Notably, ANS partially reversed the effects of 27-OHC. In conclusion, the altered cholesterol metabolism induced by 27-OHC was involved in Aβ1-42 deposition and abnormalities in both the brain tissue and synaptic structure, ultimately leading to memory loss in the ApoE ε4 transgenic mice.
  • ||||||||||  anastrozole / Generic mfg.
    Trial completion:  PHANTOM: Pulmonary Hypertension and Anastrozole Trial (clinicaltrials.gov) -  Oct 21, 2022   
    P2,  N=84, Completed, 
    We believe that this work will contribute to deepening the understanding of the loading behaviors of anticancer drugs onto nanomaterials and their interaction. Active, not recruiting --> Completed
  • ||||||||||  anastrozole / Generic mfg., tamoxifen / Generic mfg., exemestane / Generic mfg.
    Review, Journal, HEOR:  Health-Related Quality of Life in Women With Breast Cancer Undergoing Treatment With Hormonal Therapy - A Review Study. (Pubmed Central) -  Oct 18, 2022   
    It can be concluded that the QoL of postmenopausal women with breast cancer is affected by the long-term use of adjuvant endocrine therapy, with difference reported associated with the different therapies. However, further efforts are required to improve QoL instruments and the quantitative evaluation of QoL data for patients receiving adjuvant ET.
  • ||||||||||  anastrozole / Generic mfg.
    Journal:  Modelling the procoagulatory effect of Anastrozole relative to ERα and ERβ expression in breast cancer cells. (Pubmed Central) -  Oct 14, 2022   
    These results provide basic science evidence showing that the hypercoagulatory effects induced by Anastrozole treatment may be related to the tumour subphenotype. Clinical studies are required to determine whether tracking of hypercoagulatory parameters may hold value in describing subphenotypic alterations or metastatic potential during tumour progression.
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    Enrollment closed, Trial completion date, Trial primary completion date:  ASPIRE: Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis (clinicaltrials.gov) -  Oct 14, 2022   
    P2,  N=38, Active, not recruiting, 
    Clinical studies are required to determine whether tracking of hypercoagulatory parameters may hold value in describing subphenotypic alterations or metastatic potential during tumour progression. Recruiting --> Active, not recruiting | Trial completion date: Aug 2022 --> Aug 2023 | Trial primary completion date: Aug 2022 --> Aug 2023
  • ||||||||||  Man of Steel: Calcitriol-Mediated Hypercalcemia From Subcutaneous Injection of Vitamin D3 in Sesame Oil (Exhibit Hall, Orange County Convention Center, West Building) -  Oct 13, 2022 - Abstract #KIDNEYWEEK2022KIDNEY_WEEK_2911;    
    He just completed a 3 month physician-supervised body building program, taking multiple drugs to increase strength and muscle mass- including daily oral danazol 100 mg, anastrozole 1 mg, DHEA 100 mg, clomiphene citrate 50 mg, bi-weekly intramuscular HCG 10,000 IU and weekly SQ injections of vitamin D3 in sesame oil 100,000 units/mL...He was initially treated with normal saline, calcitonin and zoledronic acid 3 mcg infusion...He was treated with oral prednisone, achieving and sustaining resolution of hypercalcemia and AKI...Biopsies from those areas demonstrate a foreign body reaction with granuloma formation and express 1α-hydroxylase activity; this suggests hypercalcemia is due to increased calcitriol synthesis and intestinal calcium absorption. Our case demonstrates the dangers of abusing improper medications for body building and how providers should be vigilant to identify use of oil-based injections and its association with hypercalcemia